Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2022-04-29 Regulatory Filings
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
F-3, PROSPECTUS, SUBJECT TO COMPLETION, DATED APRIL 29, 2022
Regulatory Filings Classification · 1% confidence The document text explicitly identifies itself as a 'FORM F-3' and a 'REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933'. It details the securities being registered (Ordinary Shares, Warrants, Units) up to an aggregate offering price of $300,000,000, and mentions the intent to sell securities on a delayed or continuous basis pursuant to Rule 415. Form F-3 is the SEC registration form used by foreign private issuers (like Enlivex Therapeutics Ltd., incorporated in Israel) for shelf registrations of securities to be offered from time to time. This filing type is directly related to capital raising and financing activities, fitting best under the 'Capital/Financing Update' category, which covers fundraising and capital structure changes.
2022-04-29 English
F-3, PROSPECTUS, SUBJECT TO COMPLETION, DATED APRIL 29, 2022
Report Publication Announcement Classification · 1% confidence The document is a filing notification from ENLIVEX THERAPEUTICS LTD, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange on 29/04/2022. It explicitly states, 'Attached hereto is a report on *3-F* *ea159018-f3_enlivextherapEDGAR8_isa.pdf*'. The reference to '3-F' strongly suggests this is a notification related to the SEC Form 6-K (which is often filed by foreign private issuers, consistent with the text 'The corporation is a foreign private issuer as defined by U.S. Securities Laws'), or a similar regulatory filing document. Since the document itself is very short (1849 chars) and its primary function is to announce the attachment/publication of another report (the 3-F/6-K equivalent), it fits the definition of a Report Publication Announcement (RPA). It is not the full 10-K, IR, or ER itself, but the announcement of its availability.
2022-04-29 English
FORM 20-F 2021
Annual Report Classification · 1% confidence The document is a Form 20-F filed with the U.S. Securities and Exchange Commission (SEC). Form 20-F is the standard annual report filing for foreign private issuers, equivalent to the 10-K for domestic U.S. companies. The document explicitly identifies itself as an 'Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' for the fiscal year ended December 31, 2021. FY 2021
2022-04-29 English
FORM 20-F 2021
Report Publication Announcement Classification · 1% confidence The document is a short notification form (under 2,000 characters) submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on 20-F' and provides a filename for the attachment. According to the 'Menu vs Meal' rule, since this is a brief announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). FY 2021
2022-04-29 English
Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934" for the month of March 2022. Form 6-K is a periodic report required for foreign private issuers, which generally contains information that the company is required to disclose to its home country's securities regulator or stock exchange, or information that it makes public in press releases. The content is a press release announcing the issuance of an Israeli patent. While the 6-K itself is a regulatory filing, none of the specific codes (10-K, IR, ER, etc.) perfectly match the general nature of a Form 6-K filing that contains a press release about intellectual property. Since the document is a formal SEC filing (Form 6-K) that doesn't fit the specific categories like Annual Report (10-K), Interim Report (IR), or Earnings Release (ER), the most appropriate fallback category for a general, non-specific regulatory filing that is not otherwise categorized is 'Regulatory Filings' (RNS).
2022-03-08 English
Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells
Report Publication Announcement Classification · 1% confidence The document is very short (1765 characters) and explicitly states, "Attached hereto is a report on*6k* *6k08032022_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general SEC filing for foreign private issuers, often used for immediate reports). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA) rather than the underlying report type. Since '6K' is not a specific category, and this is an announcement of a filing, RPA is the most appropriate classification based on the provided definitions and rules.
2022-03-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.